Worldwide, cancer is a leading cause of death and is characterized by the uncontrolled growth of abnormal cells that have the ability to evade the immune system. Our latestage pipeline includes various SPEAR T-cell therapies in clinical trials across multiple solid tumors.
Afamitresgene autoleucel or “afami-cel” (formerly ADP-A2M4) is our first-generation TCR T-cell therapy targeting MAGE-A4. We began rolling submission of a BLA for afami-cel for the treatment of people with synovial sarcoma in late 2022 and aim to complete the submission in Q4 2023. We are also developing next-generation cell therapies and our first clinical candidate is ADP-A2M4CD8, currently being evaluated in the SURPASS family of trials, being investigated in the SURPASS and SURPASS-2 trials. Recently, we closed the Phase 1 ADP-A2AFP trial for people with liver cancer and will continue to focus development on new cell therapies for this disease.
Adaptimmune is developing an industry-leading T-cell therapy pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further product development.